8-K

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 4, 2015

OXiGENE, INC.

(Exact name of registrant as specified in its charter)

Delaware	0-21990	13-3679168
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

701 Gateway Boulevard, Suite 210, South San Francisco, CA 94080

(Address of principal executive offices)

Registrant’s telephone number, including area code: (650) 635-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On August 4, 2015, OXiGENE, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2015. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. This information shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

The following exhibit is furnished with this report:

Exhibit Number	Description
99.1	Press Release dated August 4, 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OXiGENE, Inc.
Date: August 4, 2015	/s/ Matthew M. Loar
	By:	Matthew M. Loar
	Chief Financial Officer

EXHIBITS

Exhibit Number	Description
99.1	Press Release dated August 4, 2015, reporting OXiGENE’s financial results for the quarter ending June 30, 2015.

EX-99.1

Exhibit 99.1

Investor and Media Contact:

ir@oxigene.com

650-635-7000

OXIGENE REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS

SOUTH SAN FRANCISCO, Calif. — August 4, 2015 — OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for treatment of cancer, today reported financial results for the quarter ended June 30, 2015.

For the second quarter of 2015, OXiGENE reported a net loss of $3.3 million compared to a net loss of $3.9 million for the comparable period in 2014. R&D expenses during the second quarter of 2015 were $2.0 million compared to $2.2 million in the second quarter of 2014. General and administrative expenses during the second quarter of 2015 were $1.3 million compared to $1.8 million in the second quarter of 2014.

At June 30, 2015, OXiGENE had cash of $33.1 million, compared to $30.0 million at December 31, 2014.

“I believe we have multiple opportunities to leverage our investigational products’ unique and demonstrated ability to block blood flow to various cancer tumors, particularly in combination with other antivascular therapies. As I mentioned last quarter, before the end of the year I look forward to presenting a clear development path for our future that we believe will optimize our pipeline assets,” said William D. Schwieterman, M.D., OXiGENE’s President and CEO.

OXiGENE also noted that it anticipates several upcoming regulatory and clinical milestones before the end of 2015. The company expects to submit a Special Protocol Assessment to the U.S. Food and Drug Administration for the potential Phase 3 study of fosbretabulin in combination with bevacizumab in platinum resistant ovarian cancer. The company plans to present results of the dose-ranging portion of the Phase 1 study of fosbretabulin in combination with pazopanib in ovarian cancer. Initial results from the ongoing Phase 1 trial in gastrointestinal neuroendocrine tumors (GI-NETs) are also scheduled to be announced. In addition, the company is on track to initiate a Phase 1 / 2 study of OXi4503 in acute myeloid leukemia (AML).

Conference Call Today

Members of OXiGENE’s management team will host a webcast and conference call today, August 4, 2015, at 4:30 p.m. EDT (1:30 p.m. PDT) to provide a second quarter 2015 financial and business update.

To listen to a live or an archived version of the audio webcast, please log on to the Company’s website, www.oxigene.com. Under the “Investors & Media” tab, select the link to “Events and Presentations.” OXiGENE’s earnings conference call can also be heard live by dialing (888) 841-3431 in the United States and Canada, or +1 (678) 809-1060 for international callers, five minutes prior to the beginning of the call. The conference ID is 32409932.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The company is focused on developing vascular disrupting agents (VDAs), which selectively disrupt abnormal blood vessels that sustain tumors. The company’s investigational drugs include fosbretabulin, which is in development as a treatment for solid tumors, and OXi4503, which is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

Safe Harbor Statement

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, data and regulatory guidance relative to our clinical programs and achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development, manufacturing and regulatory review, and the availability of additional financing to continue development of our programs. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE’s reports to the Securities and Exchange Commission, including OXiGENE’s reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

OXiGENE, Inc.

Balance Sheet Data

(Unaudited)

	June 30, 2015		December 31, 2014
	(All amounts in thousands)
Assets
Cash	$	33,093	$	30,031
Prepaid expenses and other current assets		471		322
Other assets		75		70
Total assets	$	33,639	$	30,423
Liabilities and stockholders’ equity
Accounts payable and accrued liabilities	$	1,166	$	1,419
Total stockholders’ equity		32,473		29,004
Total liabilities and stockholders’ equity	$	33,639	$	30,423

OXiGENE, Inc.

Statement of Operations Data

(Unaudited)

	Three months ended June 30,						Six months ended June 30,
	2015			2014			2015			2014
	(All amounts in thousands, except per share data)
Operating Expenses:
Research and development	$	1,981		$	2,171		$	3,650		$	3,558
General and administrative		1,347			1,753			2,455			2,994
Total operating expenses		3,328			3,924			6,105			6,552
Loss from Operations		(3,328	)		(3,924	)		(6,105	)		(6,552	)
Investment income		5			1			8			2
Other (expense) income, net		(1	)		(6	)		1			(9	)
Net loss and comprehensive loss	$	(3,324	)	$	(3,929	)	$	(6,096	)	$	(6,559	)
Basic and diluted net loss per common share attributable to common stock	$	(0.13	)	$	(0.23	)	$	(0.26	)	$	(0.50	)
Weighted-average number of common shares outstanding		26,545			17,259			23,835			13,179